Results 261 to 270 of about 67,507 (290)
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Castration-Resistant Prostate Cancer
Urologic Clinics of North America, 2017Men with advanced prostate cancer are typically treated with hormonal therapy, which results in tumor shrinkage. However, tumors relapse and develop into a highly aggressive and lethal form of the disease, termed castration-resistant prostate cancer (CRPC).
Alastair H. Davies +2 more
openaire +2 more sources
Steroidogenesis in castration-resistant prostate cancer
Urologic Oncology: Seminars and Original Investigations, 2023Castration resistance is in part attributable to aberrant activation of androgen receptor (AR) signaling by the intracrine activation of androgen precursors derived from adrenal glands. To overcome this, novel AR pathway inhibitors (ARPIs) that suppress androgen synthesis by CYP17 inhibition or AR activation by antiandrogen effects have been developed.
Masaki Shiota +4 more
openaire +2 more sources
Castration-Resistant Prostate Cancer: AUA Guideline
Journal of Urology, 2013This Guideline is intended to provide a rational basis for the management of patients with castration-resistant prostate cancer based on currently available published data.A systematic review and meta-analysis of the published literature was conducted using controlled vocabulary supplemented with keywords relating to the relevant concepts of prostate ...
Michael S, Cookson +11 more
openaire +2 more sources
Castration-Resistant Prostate Cancer: Targeted Therapies
Chemotherapy, 2011<i>Background:</i> Castration-resistant prostate cancer (CRPC) refers to patients who no longer respond to surgical or medical castration. Standard treatment options are limited. <i>Objective:</i> To review the concepts and rationale behind targeted agents currently in late-stage clinical testing for patients with CRPC. <i>
S, Leo, C, Accettura, V, Lorusso
openaire +2 more sources
Castrate-resistant prostate cancer: therapeutic strategies
Expert Opinion on Pharmacotherapy, 2010Castrate-resistant prostate cancer continues to be inadequately addressed by currently available therapies.This review will discuss recent developments, including new chemotherapies and chemotherapy regimens, antiangiogenic therapy, immunotherapy, and other new agents, such as endothelin-A receptor antagonists and clusterin inhibitors.The reader will ...
Andrea L, Harzstark, Eric J, Small
openaire +2 more sources
Overcoming castration resistance in prostate cancer
Current Opinion in Urology, 2012Recent advances in our understanding of the androgen axis signaling pathway have led to the development of therapeutic strategies to overcome the state of 'castration resistance' in prostate cancer. In this review, we examine the mechanisms of castration resistance, as well as recently reported and ongoing clinical studies, which will further identify ...
Che-Kai, Tsao +3 more
openaire +2 more sources
Immunotherapy for Castration-Resistant Prostate Cancer
Urologic Clinics of North America, 2012The improved survival with sipuleucel-T, an autologous antigen-presenting cell-based agent, for the treatment of patients with metastatic asymptomatic and minimally symptomatic castration-resistant prostate cancer supports immunotherapy as a valid approach. Also, multiple novel immunotherapeutic approaches are undergoing vigorous investigation.
Guru, Sonpavde, Philip W, Kantoff
openaire +2 more sources
New developments in castrate‐resistant prostate cancer
BJU International, 2012Castrate‐resistant prostate cancer (CRPC) occurs when disease progresses in the presence of castrate levels of androgens and remains sensitive to further hormonal manipulation. For many years the treatment of CRPC was limited to the use of docetaxel for metastatic disease.
Shore, N., Mason, M., de Reijke, Th M.
openaire +2 more sources